RE:RE:RE:RE:RE:Stay focused on the factsIf what we have already heard about TH-1902 is suggestive of better things to come, and it probably is, then new highs will be achieved. But this will be a process. We already have very good indications of safety and proof of concept which sets the stage for the next step in phase 1b (if not in phase 1a) of preliminary indications of efficacy. If TH-1902 works and is safe, it has a big future and the Sort1+ platform will grow exponentially. It is my belief we can already claim victory on safety and proof of concept but that should be confirmed in a month or two when the phase 1a results are announced. Now, most drug trials are pretty messy and the phase 1a certainly appears to have its share of ups and downs. So, I am sure not all the data we get from the phase 1a will be perfect. But it does not need to be as Wino has already shown that even already approved ADC's and other cancer drugs have all kinds of hair on them. As TH-1902 moves through the FDA trials, TH will address any issues it can, improve the timing and length of dosing and end up with the best possible candidate for FDA approval and use for those suffering from this terrible disease. Will TH-1902 cure cancer - almost certainly not. Will it meaningfully extend patients lives while being easier to tolerate - it stands a very good chance of being that when the testing is finally completed. If it is anything like that, the stock price is going much, much higher. That is why they got Fast Track status while still in the pre-clinical phase of testing (a rarity), it is why Soleus - an expert in such stocks - became the largest shreholder in the company, it is why the Chinese are interested in pursuing TH-1902 and it is why Dr. Rothenberg became a Scientific Advisor to the company. The potential in TH-1902 and maybe more so in an expanded Srot1+ platform is not a mirage and we should know 100% for sure the next important facts about TH-1902 in the not too distant future. Meanwhile, we can be about 90% assured of those same facts based on what has already been shared.
canadapiet wrote: And they lied again!!!!!!!
They said the P1a all went smoothly, just like in the preclinicals............!
Look at where we are now..........
How long are the "people in the know" saying that there is "HOPE" ?????
Well, let us all "HOPE" that in the near future (?????again....) we can set a new high !!
Momo25 - (3/23/2022 9:54:30 AM)
RE:RE:RE:Stay focused on the facts
I bought THTX when Trogarzo was lunched. At that time Dubuc talked about a potential of at least 1 billion revenue. Then everything becomes inconsistent. Legacy drugs are covering for the costs only. NASH needs huge investment and big pharmas who are making money like ever are reluctant to put a penny in this program. Oncology was brought to the table since they bought katana and the results up to now are very tiny, if not insignificant.
I averaged down many times and i am still a bit below 6$ and I took a hit of 49k by selling half of my THTX portfolio. Many shhareholders are in the same situation where I am. This is our reality today. The rest is bla..bla